Format

Send to

Choose Destination
See comment in PubMed Commons below
Urology. 2009 Sep;74(3):648-53. doi: 10.1016/j.urology.2009.02.046. Epub 2009 May 9.

XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: a meta-analysis.

Author information

1
Department of Oncology, Nanjing University School of Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.

Abstract

OBJECTIVES:

To evaluate the association between x-ray cross-complementing gene 1 (XRCC1) genetic polymorphism Arg399Gln and prostate cancer risk using a meta-analysis.

METHODS:

A comprehensive search was conducted to identify all case-control studies of XRCC1 Arg399Gln polymorphism and prostate cancer risk. Statistical analysis was performed using the software program Review Manage, version 4.2, and STATA, version 8.0.

RESULTS:

We identified 7 eligible reports, 1733 prostate cancer cases, and 1756 controls. No significant associations were observed between XRCC1 Arg399Gln polymorphism and the risk of prostate cancer in worldwide populations, without any between-study heterogeneity. In the stratified analysis by ethnicity, our results indicated a significant association and recessive genetic mode of XRCC1 Arg399Gln polymorphism with prostate cancer risk in Asian subjects. Asians with the variant Gln/Gln allele were about 43% more likely to have prostate cancer than were those with the genotype Arg/Gln or Arg/Arg. However, our results also suggested that XRCC1 Arg399Gln polymorphism was not significantly associated with prostate cancer in white men.

CONCLUSIONS:

The results of the present meta-analysis have indicated that the XRCC1 codon 399 Gln allele might act as a recessive allele in its association with prostate cancer risk in Asians only.

PMID:
19428062
DOI:
10.1016/j.urology.2009.02.046
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center